Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin in Resolving Septic Shock
NCT02716597Phase 1Terminated
- Start
- Mar 2016
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial in septic shock comparing 25% Albumin with Placebo (2 arms). Primary endpoint: Time to Cessation of Vasopressor Therapy at 28 days. Started Mar 2016; status: terminated.
02
Drugs
albumin (human)
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT02716597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716597.